Abstract Context Prostate cancer (PCa) is the most common noncutaneous malignancy and
the second leading cause of cancer mortality amongst men in the Western world. Up to 40 …

Over the past few years, we have developed an increased understanding of the molecular
mechanisms that underlie prostate cancer progression and castration resistance and …

Castration-resistant prostate cancer (CRPC) has a poor prognosis and remains a significant
therapeutic challenge. Before 2010, only docetaxel-based chemotherapy improved survival …

Context Until recently, the only approved agent for metastatic castration-resistant prostate
cancer (mCRPC) was docetaxel chemotherapy. But over the last 5 years, significant …

Historically, patients diagnosed with castration-resistant prostate cancer (CRPC) have had
poor survival rates. In recent years there have been significant advances in the treatment of …

Most men with recurrent prostate cancer (CaP) initially respond to androgen deprivation
therapy but eventually develop metastatic castration-resistant prostate cancer (CRPC). Over …

Medical oncologists who treat men with castration-resistant prostate cancer (CRPC) have
seen an abundance of new agents approved by the United States Food and Drug …

Prostate cancer is a leading cause of cancer death in men in developed countries. Once the
tumor has achieved a castration-refractory metastatic stage, treatment options are limited …

CONTEXT: Castration-resistant prostate cancer (CRPC) refers to patients who no longer
respond to surgical or medical castration. Standard treatment options are limited …

Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial
responses, almost all patients progress to castration-resistant prostate cancer (CRPC). The …